{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:49:40Z","timestamp":1790887780298,"version":"4.1.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00262-021-03094-0","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T14:02:58Z","timestamp":1635343378000},"page":"1545-1548","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Anogenital lichen sclerosus et atrophicus lesions in a case series of cancer patients on immunotherapy"],"prefix":"10.1007","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6921-714X","authenticated-orcid":false,"given":"V.","family":"Conteduca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Medri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mazzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Stanganelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"issue":"2","key":"3094_CR1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158\u2013168","journal-title":"N Engl J Med"},{"issue":"3","key":"3094_CR2","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","volume":"74","author":"SJ Hwang","year":"2016","unstructured":"Hwang SJ, Carlos G, Wakade D et al (2016) Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol 74(3):455\u201361.e1","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"3094_CR3","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","volume":"152","author":"VJ Shi","year":"2016","unstructured":"Shi VJ, Rodic N, Gettinger S et al (2016) Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol 152(10):1128\u20131136","journal-title":"JAMA Dermatol"},{"issue":"7","key":"3094_CR4","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.7150\/ijbs.34613","volume":"15","author":"DA Tran","year":"2019","unstructured":"Tran DA, Tan X, Macri CJ, Goldstein AT, Fu SW (2019) Lichen Sclerosus: an autoimmunopathogenic and genomic enigma with emerging genetic and immune targets. Int J Biol Sci 15(7):1429\u20131439","journal-title":"Int J Biol Sci"},{"key":"3094_CR5","doi-asserted-by":"publisher","first-page":"238","DOI":"10.2340\/00015555-1512","volume":"93","author":"A Kreuter","year":"2013","unstructured":"Kreuter A, Kryvosheyeva Y, Terras S et al (2013) Association of autoimmune diseases with lichen sclerosus in 532 male and female patients. Acta Derm Venereol 93:238\u2013241","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"3094_CR6","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/1346-8138.14171","volume":"45","author":"M Hasegawa","year":"2018","unstructured":"Hasegawa M, Ishikawa O, Asano Y et al (2018) Diagnostic criteria, severity classification and guidelines of lichen sclerosus et atrophicus. J Dermatol 45(8):891\u2013897","journal-title":"J Dermatol"},{"issue":"4","key":"3094_CR7","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/bjd.16241","volume":"178","author":"FM Lewis","year":"2018","unstructured":"Lewis FM, Tatnall FM, Velangi SS et al (2018) British association of dermatologists guidelines for the management of lichen sclerosus. Br J Dermatol 178(4):839\u2013853","journal-title":"Br J Dermatol"},{"issue":"1","key":"3094_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1159\/000439198","volume":"232","author":"A Borghi","year":"2016","unstructured":"Borghi A, Corazza M, Minghetti S, Bianchini E, Virgili A (2016) Dermoscopic features of vulvar lichen sclerosus in the setting of a prospective cohort of patients: new observations. Dermatology 232(1):71\u201377","journal-title":"Dermatology"},{"key":"3094_CR9","doi-asserted-by":"publisher","first-page":"573527","DOI":"10.3389\/fonc.2020.573527","volume":"10","author":"SM Seyed Jafari","year":"2020","unstructured":"Seyed Jafari SM, Feldmeyer L, Hunger RE (2020) Development of extragenital lichen sclerosus in malignant melanoma patients treated with ipilimumab in combination with nivolumab. Front Oncol. 10:573527","journal-title":"Front Oncol."},{"issue":"3","key":"3094_CR10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/ced.14092","volume":"45","author":"N di Meo","year":"2020","unstructured":"di Meo N, Conforti C, Corneli P et al (2020) Nivolumab-associated extragenital lichen sclerosus et atrophicus. Clin Exp Dermatol 45(3):350\u2013352","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"3094_CR11","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/j.1365-2133.2010.09997.x","volume":"163","author":"SM Neill","year":"2010","unstructured":"Neill SM, Lewis FM, Tatnall FM, Cox NH, Association of Dermatologists B (2010) British Association of Dermatologists\u2019 guidelines for the management of lichen sclerosus 2010. Br J Dermatol 163(4):672\u2013682","journal-title":"Br J Dermatol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-03094-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-021-03094-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-03094-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T02:04:47Z","timestamp":1653098687000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-021-03094-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["3094"],"URL":"https:\/\/doi.org\/10.1007\/s00262-021-03094-0","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]},"assertion":[{"value":"21 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"V. Conteduca received speaker honoraria or travel support from Astellas, Janssen-Cilag, and Sanofi-Aventis. V. Conteduca received consulting fee from Bayer and is an advisory board member of Janssen, Astellas, AstraZeneca, and Merck. U. De Giorgi reports grants from AstraZeneca; personal fees from Astellas, Bayer, Novartis, Merck Sharp & Dohme, and Pharmamar; grants and personal fees from Sanofi; grants and non-financial support from Roche; and personal fees and non-financial support from Janssen-Cilag, Pfizer, Bristol Myers Squibb, and Ipsen. No potential conflicts of interest were disclosed by the other authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}